Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Sep 2009 Planned end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 15 Dec 2008 Genentech and Eli Lilly reported as trial sponsor by ClinicalTrials.gov.
- 17 Jun 2008 Identifier added (BRSMTS0007) as reported by ClinicalTrials.gov.